ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2013
Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
190 citing papers in PubMed, 1 synthesis or guideline pooled it, 358 citations in OpenAlex.
- Prognostic significance of matrix metalloproteinase-7 in gastric cancer survival: a meta-analysis.PloS one · 2014Pooled it
- IL-17A/IL-17RA promotes invasion and activates MMP-2 and MMP-9 expression via p38 MAPK signaling pathway in non-small cell lung cancer.Molecular and cellular biochemistry · 2019Trial
- Understanding and targeting the tumour matrisome.Nature reviews. Clinical oncology · 2026Review
- From epigenetics to metastasis: Multifaceted roles of lncRNAs in gastric cancer.Biochemistry and biophysics reports · 2026Review
- Acetogenins fromACS omega · 2026Article
- Aptamer-Based Strategies for Colorectal Cancer Detection: Emerging Technologies and Future Directions.Biosensors · 2025Review
- Engineered N-TIMP2 Variant Specifically Targeting MMP-9 Exhibits Potent Anti-Glioblastoma Activity.Biomolecules · 2025Article
- Evidence for the Prognostic Value of CDH17 Expression in Colorectal Carcinoma.International journal of molecular sciences · 2025Article
- Natural bioactive gallic acid shows potential anticancer effects by inhibiting the proliferation and invasiveness behavior in human embryonic carcinoma cells.Molecular medicine reports · 2025Article
- High intra-tumoral and serum matrix metalloproteinase 9 levels are associated with reduced survival of patients with glioblastoma and brain metastases.Frontiers in oncology · 2025Article
- Translationally Controlled Tumor Protein Enhances Angiogenesis in Ovarian Tumors by Activating Vascular Endothelial Growth Factor Receptor 2 Signaling.Biomolecules & therapeutics · 2025Article
- Syndecan-1 and E-Cadherin Expression in Canine Cutaneous Squamous Cell Carcinoma.Veterinary sciences · 2024Article
- Matrix Metalloproteinases on Skin Photoaging.Journal of cosmetic dermatology · 2024Review
- Engineered TIMP2 with narrow MMP-9 specificity is an effective inhibitor of invasion and proliferation of triple-negative breast cancer cells.The Journal of biological chemistry · 2024Article
- Exploring Label-Free Imaging Techniques with Copper Sulfide Microspheres for Observing Breast Cancer Cells.ACS omega · 2024Article
- Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions.Nature communications · 2024Article
- Programmed Death-Ligand (PD-L1), Epidermal Growth Factor (EGF), Relaxin, and Matrix Metalloproteinase-3 (MMP3): Potential Biomarkers of Malignancy in Canine Mammary Neoplasia.International journal of molecular sciences · 2024Article
- Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC).Oncology research · 2024Article
- Matrine inhibits hepatocellular carcinoma cell malignancy through the circ_0013290/miR-139-5p/MMP16 pathway.Histology and histopathology · 2023Article
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
130 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers are used as tools in cancer diagnostics and in treatment stratification. In most cancers, there are increased levels of one or several members of the matrix metalloproteinases (MMPs). This is a family of proteolytic enzymes that are involved in many phases of cancer progression, including angiogenesis, invasiveness, and metastasis. It has therefore been expected that MMPs could serve as both diagnostic and prognostic markers in cancer patients, but despite a huge number of studies, it has been difficult to establish MMPs as cancer biomarkers. In the present paper, we assess some of the challenges associated with MMP research as well as putative reasons for the conflicting data on the value of these enzymes as diagnostic and prognostic markers in cancer patients. We also review the prognostic value of a number of MMPs in patients with lung, colorectal, breast, and prostate cancers. The review also discusses MMPs as potential target molecules for therapeutic agents and new strategies for development of such drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.